The rationale for investigating an intermittent binimetinib dosing schedule arose from preclinical data supporting that pretreatment with a MEK inhibitor resulted in synergistic antitumor activity in cancer cell lines as well as in vivo data showing that intermittent binimetinib dosing enhanced the activity of conventional cytotoxic agents [7, 14]. This evidence concerns the gene MAP2K7 and cancer.